Group 1 - The 2025 National Medical Insurance Drug List includes 114 new drugs, with 50 being innovative drugs, showing an overall success rate of 88%, an increase from 76% in 2024 [1] - Nine innovative drugs from the Sci-Tech Innovation Board have been included in the medical insurance list, highlighting the strength and vitality of these companies [1] - The first version of the Commercial Health Insurance Innovative Drug List has been released, complementing the basic medical insurance and providing new possibilities for patients to access cutting-edge treatments [4] Group 2 - Nearly 90% of new drugs approved by Sci-Tech Innovation Board companies have received medical insurance support, indicating a shift towards value realization for these companies [2] - The drug "Junshi Biological's Junshida" is the only domestic PCSK9-targeted drug for patients intolerant to statins, now included in the medical insurance list [2] - The successful renewal negotiations for several innovative drugs confirm their clinical value and market position, benefiting a wider patient population [6][7] Group 3 - Innovative drugs from companies like Baiji Shenzhou and Junshi Biological have been recognized for their clinical value and patient benefits, leading to their inclusion in the medical insurance list [7] - The R&D investment of Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10%, indicating a strong commitment to innovation [7] - The cycle of "R&D investment - innovation results - insurance support - market return - reinvestment in R&D" is being established and strengthened within the industry [7]

Core Insights - The new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory will be implemented nationwide starting January 1, 2026, showcasing the government's commitment to enhancing healthcare access [1] Group 1: National Medical Insurance Directory - Nine innovative drugs from the STAR Market have been included in the new National Medical Insurance Directory, highlighting the strength and vitality of innovative pharmaceutical companies [1] - The inclusion of products like Baiyue Shenzhou's Baihe An and Kaize Bai in the first Commercial Health Insurance Innovative Drug Directory provides broader payment pathways for cutting-edge treatments [1][4] Group 2: Innovative Drug Companies - Nearly 90% of STAR Market biopharmaceutical companies have received medical insurance support for their newly approved drugs, indicating a favorable environment for innovation [2] - Junshi Biosciences' drug, Junshida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance directory [2] - Haichuang Pharmaceutical's first marketed drug, Hainan An, is set to launch in May 2025 for treating metastatic castration-resistant prostate cancer, with its inclusion in the 2025 medical insurance directory expected to enhance market promotion and patient accessibility [2] Group 3: Drug Development and Market Integration - New cancer drugs from companies like Shanghai Ailis and Yifang Biotech provide precise treatment options for major diseases, demonstrating the efficient integration of new drug reviews and medical insurance payments in China [3] - Successful renewal negotiations for innovative drugs from companies like Baiyue Shenzhou and Junshi Biosciences further expand medical insurance coverage, benefiting a wider patient population [5] Group 4: R&D Investment and Future Outlook - R&D investment among STAR Market innovative drug companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall A-share level [6] - The continuous improvement and collaboration of support policies like medical insurance and commercial insurance are expected to foster the emergence of more world-class new drugs, contributing to the health of the Chinese population [6]

Core Insights - The 2025 National Medical Insurance Drug List includes 114 new drugs, with 50 being innovative drugs, achieving an overall success rate of 88%, a significant increase from 76% in 2024 [1] - The first version of the commercial insurance innovative drug list includes 19 drugs, laying the foundation for a multi-tiered medical security system [1] - The inclusion of nine innovative drugs from the Sci-Tech Innovation Board in the medical insurance list highlights the robust capabilities and vitality of these companies [1] Group 1: Innovative Drug Inclusion - Nine innovative drugs from Sci-Tech Innovation Board companies have been included in the medical insurance list, with several others successfully renewing or expanding their indications [1] - Junshi Biosciences' drug, Juntai® (generic name: Angrexis monoclonal antibody injection), is the only domestic PCSK9-targeted drug for patients intolerant to statins included in the new list [2] - Haichuang Pharmaceutical's first marketed drug, Hainaan® (generic name: Dihydrotestosterone enzalutamide soft capsule), received approval for market launch and is included in the 2025 medical insurance list, enhancing patient access [2] Group 2: Commercial Insurance Innovations - The first commercial health insurance innovative drug list complements the basic medical insurance, providing new possibilities for patients to access cutting-edge treatments [4] - Two advanced therapy drugs from BeiGene, including Baihe An® (generic name: Zhenidat monoclonal antibody injection), are among the first to be included in the commercial insurance list, marking a significant market access pathway for high-value innovative drugs [4] Group 3: Renewal and Expansion of Indications - Successful renewals of innovative drugs confirm their clinical value and market position, with BeiGene's Bai Ze An® (generic name: Tarelizumab injection) and Junshi Biosciences' Tuoyi® (generic name: Toripalimab injection) expanding their insurance coverage [5][6] - Junshi Biosciences' Tuoyi® has now been included for 12 indications in the national medical insurance list, showcasing the recognition of its clinical value and innovation by the National Medical Insurance Bureau [6] Group 4: R&D Investment and Development Cycle - Sci-Tech Innovation Board companies have maintained a high level of R&D investment, with total R&D spending reaching a new high in the first three quarters of 2025, growing over 10% year-on-year [6] - The R&D intensity of these companies stands at 42%, significantly surpassing the overall level of A-shares during the same period, indicating a solid cycle of "R&D investment - innovative results - insurance support - market returns - reinvestment in R&D" [6][7]

厦门特宝生物工程股份有限公司 2025 年第一次临时股东大会 会议资料 （688278） 中国·厦门 厦门特宝生物工程股份有限公司 2025 年第一次临时股东大会会议资料 会议须知 为保障厦门特宝生物工程股份有限公司（以下简称"公司"）全体股东 的合法权益，维护股东大会的正常秩序，确保本次股东大会顺利召开，根据 《公司章程》《股东大会议事规则》及有关法律法规的规定，特制定本须知， 望出席股东大会的全体人员遵照执行。 一、本公司董事会办公室具体负责会议的程序安排和会务工作。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东及股东 代理人的合法权益，除出席会议的股东及股东代理人、公司董事、监事、高 级管理人员、公司聘请的律师及董事会邀请的人员外，公司有权依法拒绝其 他人员进入会场。 三、为保障本次股东大会的顺利召开，股东及股东代理人须在会议召 开前 30 分钟到会议现场办理签到手续，并按规定出示证券账户卡、身份证 明文件或企业营业执照/注册证书复印件（加盖公章）、授权委托书等，经 验证后方可出席会议。 四、本次股东大会采取现场投票和网络投票相结合的方式表决，结合 现场投票和网络投票的表决结果发布股东大会决议 ...

Group 1 - Company: Rockchip (603893) is a local chip design company based in Fuzhou, specializing in AIoT system-level chip development, design, and sales, with a complete SoC chip R&D capability [1][20] - Core products include flagship AIoT SoCs, edge AI co-processors, and visual processing chips, catering to high computing power needs across various scenarios [1][20] - The company benefits from favorable policies under Fujian's "14th Five-Year Plan" for digital economy and semiconductor industry support, as well as tax incentives and R&D subsidies from the free trade zone [1][20] Group 2 - Company: Yealink (300628) is a leading global provider of communication and collaboration solutions, headquartered in Xiamen, with products sold in over 140 countries [2][21] - Core business focuses on unified communication, including cloud + endpoint video conferencing systems and IP voice communication devices, forming a complete business loop with major partnerships [2][21] - The company is expected to benefit from cross-border data flow facilitation policies in the Fujian free trade zone, enhancing international business expansion efficiency [2][21] Group 3 - Company: Xiamen Tungsten (688778) is a leading enterprise in the field of lithium-ion battery cathode materials, focusing on R&D, production, and sales of ternary materials and lithium iron phosphate materials [3][23] - The company is positioned to benefit from policies supporting advanced equipment manufacturing and new energy industries under Fujian's "5+5+5" industrial cluster [3][23] - Market demand for core products is expected to rise due to the dual drivers of high nickel battery development and explosive growth in the energy storage industry [3][23] Group 4 - Company: Aerospace Development (000547) is a state-controlled technology enterprise in Xiamen, playing a key role in military electronic information and actively engaging in civil emerging industries [4][24] - Core business includes electronic blue army, communication networks, electromagnetic security, and satellite navigation, providing full-chain service capabilities [4][24] - The company is likely to gain more military orders and provincial support under the "14th Five-Year Plan" for national defense informationization and commercial aerospace [4][24] Group 5 - Company: Teva Biopharmaceuticals (688278) is a national high-tech enterprise in Xiamen, focusing on the R&D, production, and sales of recombinant protein drugs for chronic disease treatment [5][25] - The company is positioned to benefit from relaxed entry policies for the biopharmaceutical industry in the Fujian free trade zone, facilitating the introduction of advanced technologies [5][25] - The company is expected to receive increased R&D subsidies and medical insurance support under the "14th Five-Year Plan" for health initiatives in Fujian [5][25] Group 6 - Company: Kehua Data (002335) is a leading provider of new energy power solutions in China, with a focus on data center power systems, energy storage systems, and new energy generation equipment [6][26] - The company is expected to see increased order demand driven by the dual growth of the "East Data West Computing" project and the energy storage industry [6][26] - The company benefits from cross-border power equipment import and export facilitation policies in the Fujian free trade zone, accelerating international business expansion [6][26] Group 7 - Company: Jianfa Co., Ltd. (600153) is a large state-controlled enterprise in Xiamen, focusing on supply chain operations and real estate development [7][27] - The company provides comprehensive supply chain services for bulk commodities, including procurement, warehousing, transportation, and sales [7][27] - The company is expected to benefit from policies facilitating cross-border trade and logistics in the Fujian free trade zone, enhancing operational efficiency [7][27] Group 8 - Company: Fuzhou Energy (600483) is a state-owned energy enterprise in Fujian, focusing on power generation, coal trading, and new energy development [8][29] - The company aims to build a clean, low-carbon, and efficient energy system, with a focus on renewable energy projects [8][29] - The company is expected to receive increased subsidies for wind and solar projects under the "14th Five-Year Plan" for new energy system construction [8][29] Group 9 - Company: Anjijia Foods (603345) is a leading frozen food enterprise in China, specializing in the R&D, production, and sales of frozen hot pot ingredients and prepared dishes [9][30] - The company is positioned to benefit from policies facilitating food export and inspection optimization in the Fujian free trade zone, accelerating overseas business expansion [9][30] - The company is expected to receive increased support for R&D innovation under the "14th Five-Year Plan" for rural revitalization and food industry upgrades [9][30] Group 10 - Company: Newland (000997) is a leading IoT enterprise in Fuzhou, focusing on smart payment terminals, IoT devices, and digital identity solutions [10][31] - The company is expected to benefit from policies supporting digital trade and cross-border payment facilitation in the Fujian free trade zone [10][31] - The company is positioned to become a core player in cross-strait digital payment and IoT cooperation, receiving provincial R&D funding support [10][31] Group 11 - Company: Xiamen Xiangyu (600057) is a large state-owned supply chain enterprise, focusing on bulk commodity supply chain operations [11][32] - The company provides comprehensive services including warehousing, transportation, processing, trade, and finance [11][32] - The company is expected to benefit from policies optimizing bonded logistics and cross-border trade facilitation in the Fujian free trade zone [11][32] Group 12 - Company: Sankeshu (603737) is a leading paint enterprise in China, focusing on environmentally friendly coatings and construction materials [12][34] - The company is expected to benefit from policies supporting green industries and construction material upgrades under Fujian's "14th Five-Year Plan" [12][34] - The company aims to reduce high-end raw material procurement costs through customs facilitation policies in the free trade zone [12][34] Group 13 - Company: Kaiying Network (002517) is a comprehensive gaming enterprise in Xiamen, focusing on game development, publishing, and operation [13][35] - The company is expected to benefit from policies supporting digital economy and cultural industry development under Fujian's "14th Five-Year Plan" [13][35] - The company aims to enhance overseas game publishing efficiency through cross-border cultural trade facilitation policies [13][35] Group 14 - Company: Tengjing Technology (688195) is a national high-tech enterprise focusing on the R&D, production, and sales of optoelectronic devices [14][36] - The company is expected to benefit from policies supporting digital economy and optoelectronic industry development under Fujian's "14th Five-Year Plan" [14][36] - The company aims to deepen its layout in the high-end optoelectronic field with provincial R&D funding support [14][36] Group 15 - Company: Fuzhou Crystal Technology (002222) is a leading global crystal device enterprise, focusing on the R&D, production, and sales of optical crystals and laser devices [15][37] - The company is expected to benefit from policies supporting semiconductor and optoelectronic industry development under Fujian's "14th Five-Year Plan" [15][37] - The company aims to enhance its market position through provincial R&D subsidies and project cooperation opportunities [15][37] Group 16 - Company: Zhongmin Energy (600163) is a state-owned new energy enterprise in Fujian, focusing on wind and solar energy development [16][38] - The company aims to accelerate its renewable energy project layout under carbon peak and carbon neutrality goals [16][38] - The company is expected to receive increased support for wind and solar projects under Fujian's "14th Five-Year Plan" for new energy system construction [16][38]

Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have announced the inclusion of the new drug Yipeisheng (generic name: Yipei Growth Hormone Injection) developed by TeBao Bioengineering Co., Ltd. in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 Edition), effective from January 1, 2026, which will enhance drug accessibility and reduce the medication burden for a wider range of patients with dwarfism [1][2] - The prevalence of dwarfism among children in China is approximately 3%, corresponding to about 7.6 million patients, but the standardized treatment rate is less than 5%, with traditional treatment options being a significant limiting factor [1] - Yipeisheng is the world's first Y-type 40kD polyethylene glycol long-acting growth hormone, primarily used for treating growth retardation due to growth hormone deficiency in children aged 3 and above, featuring a structural modification that preserves biological activity and allows for weekly administration [1] Group 2 - TeBao Bio has focused on the research and development of long-acting protein drugs, particularly excelling in polyethylene glycol modification technology, establishing itself as a leading enterprise in the domestic long-acting protein field after nearly 30 years of technological accumulation [2] - In the first three quarters of 2025, the company's R&D investment reached 312 million yuan, a year-on-year increase of 38.53%, providing strong support for continuous innovation [2] - The company aims to continue increasing R&D efforts to launch more high-quality and accessible innovative treatment solutions, contributing to the standardized diagnosis and treatment of dwarfism and benefiting more children and families, aligning with the "Healthy China 2030" strategy [2]

Group 1 - The A-share market experienced fluctuations with the innovative drug sector showing a rebound before retreating, as evidenced by the performance of the Science and Technology Innovation Drug ETF Huatai (589120) which was flat after initially rising over 1% [1] - The Science and Technology Innovation Drug ETF Huatai (589120) has seen net inflows exceeding 9.39 million yuan over the past five days, with funds entering the market intermittently [1] - The component stocks of the ETF showed mixed performance, with stocks like Ailisi and Baili Tianheng rising over 1%, while others like Maiwei Biology fell over 2% [3][4] Group 2 - The 2025 National Basic Medical Insurance Drug Directory has been adjusted, adding 114 new drugs, including 50 first-class innovative drugs, which reflects ongoing support for innovation in the pharmaceutical sector [5][6] - The adjustment of the drug directory aims to encourage innovation while ensuring basic healthcare needs, with a focus on "true innovation" and "differentiated innovation" [6] - The commercial insurance directory has included 19 drugs, including CAR-T and treatments for Alzheimer's disease, indicating a significant step towards expanding commercial medical insurance in China [6] Group 3 - The innovative drug sector is expected to maintain a high level of activity, with a focus on "data validation" and "value reassessment" as key investment themes [6][7] - The industry is entering an internationalization phase, with business development (BD) becoming a regular practice, and the verification of global product value being crucial for future growth [7] - The Science and Technology Innovation Drug ETF Huatai (589120) focuses on leading innovative drug companies, providing a higher degree of exposure to the opportunities presented by the rise of innovative drugs in China [7]

12月9日早盘，A股、港股创新药概念均表现活跃。热门ETF中，创新药ETF（159992）截至9:57涨约 1%，成交额超1.5亿元。 成分股来看，迪哲医药、恒瑞医药、泰格医药等涨幅居前；通化金马、人福医药、特宝生物等小幅领 跌。 消息面上，2025年国家医保药品目录及首版商保创新药目录在广州发布。2025年国家医保药品目录成功 新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。19种药品纳入首 版商保创新药目录。 每日经济新闻 中信建投认为，国家医保谈判成功率创新高，商保目录有望成为重要增量，政策鼓励创新药发展。与此 同时，中国创新药管线国际化竞争力持续提升，出海模式持续升级，新技术推动行业快速发展。看好相 关创新药及制药企业。 资料显示，创新药ETF（159992，场外联接A类：012781；C类：012782）紧密跟踪中证创新药产业指 数，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的整体表 现。 ...

在乙肝领域，特宝生物支持的"珠峰项目"为无数患者带来了临床治愈的希望；在儿科领域，益佩生®同 样承载着这样的使命——让更多矮小症患儿不仅能"用得起"长效生长激素，更能"用得好、用得安全"。 此次益佩生®纳入医保，将显著提升药物的可及性，降低患者家庭经济负担，让高品质创新药"飞入寻 常百姓家"。而企业对高标准、无防腐剂等生产工艺的坚守，则确保了药品在可及性提升的同时，始终 保持安全可靠的品质和疗效。这种"可及性"与"高质量"的统一，正是特宝生物"以患者为中心"承诺的最 佳注脚。 展望2026年，随着新版医保目录的落地执行，益佩生®有望继派格宾®之后，成为驱动特宝生物业绩增 长的第二引擎。而对于资本市场而言，一家始终将技术创新聚焦于解决实际临床问题的公司，其长期成 长逻辑已然清晰可见。 此次进入医保，对于特宝生物而言意义深远，不仅标志着产品获得国家级市场准入资格，更在医保谈 判"保基本"的大背景下，验证了一个核心商业命题：具备显著临床优势和更高安全性的差异化创新药， 才能获得认可与支持。 益佩生®能够顺利入局，得益于其扎实的"品质硬实力"，尤其是其在分子设计层面的突破性创新和安全 性升级，为产品构建了难以复制的差 ...

Core Viewpoint - The successful inclusion of Teva Biopharma's long-acting growth hormone, Yipei Growth Hormone Injection (brand name: Yipei®), into the medical insurance directory signifies a major milestone for the company, highlighting the importance of differentiated innovative drugs with significant clinical advantages and higher safety in gaining recognition and support [1][2] Group 1 - The inclusion of Yipei® in the medical insurance directory marks national market access for the product, validating the company's core business proposition [1] - Yipei®'s successful entry is attributed to its strong "quality hard power," particularly breakthroughs in molecular design and safety upgrades, creating a difficult-to-replicate competitive advantage [1] - Teva Biopharma has focused on high-barrier biotechnological advancements, translating them into clinical benefits that address user pain points [1] Group 2 - The "Zhu Feng Project" supported by Teva Biopharma has provided clinical cure hope for numerous hepatitis B patients, while Yipei® aims to ensure that more children with growth disorders can access and safely use long-acting growth hormones [2] - The inclusion of Yipei® in the medical insurance directory is expected to significantly enhance drug accessibility and reduce the financial burden on patients' families, allowing high-quality innovative drugs to reach ordinary households [2] - By adhering to high standards and preservative-free production processes, the company ensures that increased accessibility does not compromise the safety and efficacy of its products [2]